The US Food and Drug Administration (FDA) has ordered label changes for bluebird bio's Skysona (elivaldogene autotemcel) due to blood cancer risks associated with the gene therapy product.

Shares of Florida-USA-based drug developer Veru fell more than 4% to $3.58 in early trading, after it announced selection of ...

Indian cell therapy company Eyestem Research has raised $10 million in a significantly oversubscribed funding round to ...

Vinay Prasad has returned to lead the US regulator’s Center for Biologics Evaluation and Research, resuming responsibility ...

The US Food and Drug Administration’s (FDA) recent moves around GLP-1-based combination therapies are telling, not just about ...

Chinese drugmaker Kexing Biopharm (SHA: 688136) has entered a strategic partnership with US life sciences services group ...

Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with ...

US clinical-stage biotech Vor Bio has announced the appointment of Dallan Murray as chief commercial officer, effective ...

The Gates Foundation announced a $2.5 billion commitment through 2030 to accelerate research and development (R&D) focused ...

Significant news last week included Vertex Pharmaceuticals dropping development of its acute pain candidate VX-993 following ...